SUBSCRIBE
SUBSCRIBE

Indications

PRESS RELEASES
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
September 30, 2025
 · 
7 min read
Press Releases
Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate
September 23, 2025
 · 
2 min read
Press Releases
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
September 22, 2025
 · 
19 min read
Press Releases
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
September 22, 2025
 · 
19 min read
Press Releases
Health Canada approves Celltrion’s Stoboclo® and Osenvelt®(CT-P41), denosumab biosimilars for the treatment of all indications approved for the reference products, Prolia® and Xgeva®, respectively
September 19, 2025
 · 
5 min read
Press Releases
Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
September 15, 2025
 · 
4 min read
Press Releases
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
September 8, 2025
 · 
12 min read
Press Releases
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
August 21, 2025
 · 
4 min read
Press Releases
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
August 7, 2025
 · 
8 min read
Press Releases
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
July 24, 2025
 · 
10 min read
Press Releases
Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
July 21, 2025
 · 
6 min read
Press Releases
Acera Surgical Broadens Reach of Restrata® with New FDA Clearance for Soft Tissue Reinforcement
June 26, 2025
 · 
2 min read
Press Releases
FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients
June 25, 2025
 · 
9 min read
Press Releases
AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)
June 19, 2025
 · 
3 min read
Press Releases
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
June 17, 2025
 · 
10 min read
Press Releases
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
June 12, 2025
 · 
10 min read
Press Releases
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
June 9, 2025
 · 
4 min read
Press Releases
Akeso’s PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab
June 5, 2025
 · 
6 min read
Press Releases
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
June 4, 2025
 · 
6 min read
Press Releases
New Subcutaneous Formulation of OPDIVO® Approved in Canada for Use Across All Authorized Solid Tumour Indications
May 28, 2025
 · 
5 min read
Load More